[A18-45] Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2018
Commission awarded on 05.07.2018 by the Federal Joint Committee (G-BA).
First-line treatment of adults with locally advanced or metastatic NSCLC (lung cancer) with activating EGFR mutations
EGFR mutations in exon 21 (L858R) or exon 19 deletion: Hint of non-quantifiable added benefit. Other activating EGFR mutations: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A17-20||Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-14||Osimertinib - Benefit assessment according to §35a Social Code Book V||Commission completed|